vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and HARTE HANKS INC (HHS). Click either name above to swap in a different company.
HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $37.2M, roughly 1.1× GYRE THERAPEUTICS, INC.). HARTE HANKS INC runs the higher net margin — 5.5% vs -3.7%, a 9.2% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -6.4%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
GYRE vs HHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $39.9M |
| Net Profit | $-1.4M | $2.2M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | -0.3% |
| Net Margin | -3.7% | 5.5% |
| Revenue YoY | 33.4% | -15.4% |
| Net Profit YoY | -340.1% | — |
| EPS (diluted) | $-0.01 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $39.9M | ||
| Q3 25 | $30.6M | $39.5M | ||
| Q2 25 | $26.8M | $38.6M | ||
| Q1 25 | $22.1M | $41.6M | ||
| Q4 24 | $27.9M | $47.1M | ||
| Q3 24 | $25.5M | $47.6M | ||
| Q2 24 | $25.2M | $45.0M | ||
| Q1 24 | $27.2M | $45.4M |
| Q4 25 | $-1.4M | $2.2M | ||
| Q3 25 | $5.9M | $-2.3M | ||
| Q2 25 | $1.6M | $-335.0K | ||
| Q1 25 | $3.7M | $-392.0K | ||
| Q4 24 | $569.0K | — | ||
| Q3 24 | $2.9M | $142.0K | ||
| Q2 24 | $4.5M | $-27.8M | ||
| Q1 24 | $9.9M | $-171.0K |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | -0.3% | ||
| Q3 25 | 22.7% | 1.3% | ||
| Q2 25 | 8.1% | 0.1% | ||
| Q1 25 | 10.3% | -0.1% | ||
| Q4 24 | 2.4% | -3.3% | ||
| Q3 24 | 16.6% | 4.0% | ||
| Q2 24 | 12.7% | 3.0% | ||
| Q1 24 | 29.7% | 0.8% |
| Q4 25 | -3.7% | 5.5% | ||
| Q3 25 | 19.4% | -5.8% | ||
| Q2 25 | 5.9% | -0.9% | ||
| Q1 25 | 16.9% | -0.9% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 11.2% | 0.3% | ||
| Q2 24 | 18.0% | -61.8% | ||
| Q1 24 | 36.6% | -0.4% |
| Q4 25 | $-0.01 | $0.30 | ||
| Q3 25 | $0.03 | $-0.31 | ||
| Q2 25 | $0.00 | $-0.05 | ||
| Q1 25 | $0.00 | $-0.05 | ||
| Q4 24 | $0.00 | $-0.31 | ||
| Q3 24 | $0.01 | $0.02 | ||
| Q2 24 | $0.01 | $-3.84 | ||
| Q1 24 | $0.03 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $20.5M |
| Total Assets | $166.1M | $91.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $5.6M | ||
| Q3 25 | $60.0M | $6.5M | ||
| Q2 25 | $54.4M | $4.8M | ||
| Q1 25 | $29.9M | $9.0M | ||
| Q4 24 | $26.7M | $9.8M | ||
| Q3 24 | $25.1M | $5.9M | ||
| Q2 24 | $25.1M | $11.0M | ||
| Q1 24 | $37.4M | $11.5M |
| Q4 25 | $106.0M | $20.5M | ||
| Q3 25 | $101.9M | $19.9M | ||
| Q2 25 | $92.0M | $22.2M | ||
| Q1 25 | $68.1M | $21.4M | ||
| Q4 24 | $63.3M | $21.7M | ||
| Q3 24 | $63.2M | $21.0M | ||
| Q2 24 | $60.4M | $20.6M | ||
| Q1 24 | $56.6M | $20.0M |
| Q4 25 | $166.1M | $91.8M | ||
| Q3 25 | $159.4M | $92.7M | ||
| Q2 25 | $152.6M | $95.0M | ||
| Q1 25 | $129.8M | $100.6M | ||
| Q4 24 | $125.4M | $101.8M | ||
| Q3 24 | $125.2M | $108.1M | ||
| Q2 24 | $120.9M | $109.7M | ||
| Q1 24 | $122.0M | $113.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $737.0K |
| Free Cash FlowOCF − Capex | $-5.8M | $-686.0K |
| FCF MarginFCF / Revenue | -15.5% | -1.7% |
| Capex IntensityCapex / Revenue | 0.4% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $-4.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $737.0K | ||
| Q3 25 | $4.7M | $3.2M | ||
| Q2 25 | $2.1M | $-4.8M | ||
| Q1 25 | $-129.0K | $-818.0K | ||
| Q4 24 | $-2.8M | $4.0M | ||
| Q3 24 | $1.7M | $-2.9M | ||
| Q2 24 | $-5.5M | $1.6M | ||
| Q1 24 | $2.9M | $-5.7M |
| Q4 25 | $-5.8M | $-686.0K | ||
| Q3 25 | $4.0M | $2.2M | ||
| Q2 25 | $1.8M | $-5.1M | ||
| Q1 25 | $-251.0K | $-923.0K | ||
| Q4 24 | $-2.8M | $3.4M | ||
| Q3 24 | $1.0M | $-4.9M | ||
| Q2 24 | $-6.9M | $926.0K | ||
| Q1 24 | $2.7M | $-6.2M |
| Q4 25 | -15.5% | -1.7% | ||
| Q3 25 | 13.1% | 5.5% | ||
| Q2 25 | 6.8% | -13.1% | ||
| Q1 25 | -1.1% | -2.2% | ||
| Q4 24 | -10.1% | 7.3% | ||
| Q3 24 | 4.1% | -10.2% | ||
| Q2 24 | -27.5% | 2.1% | ||
| Q1 24 | 9.8% | -13.7% |
| Q4 25 | 0.4% | 3.6% | ||
| Q3 25 | 2.2% | 2.5% | ||
| Q2 25 | 1.0% | 0.6% | ||
| Q1 25 | 0.6% | 0.3% | ||
| Q4 24 | 0.2% | 1.3% | ||
| Q3 24 | 2.7% | 4.0% | ||
| Q2 24 | 5.8% | 1.5% | ||
| Q1 24 | 0.9% | 1.2% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | -20.76× | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
